RP
HBIO icon

Riverwater Partners’s Harvard Bioscience HBIO Stock Holding History

Riverwater Partners’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,341
Closed -$265K – 222
2024
Q3 		$265K Sell
10,341
-257
-2% -$7.57K 0.13% 178
2024
Q2 		$302K Buy
10,598
+1,278
+14% +$44.8K 0.22% 139
2024
Q1 		$395K Buy
9,320
+1,149
+14% +$51.7K 0.29% 107
2023
Q4 		$437K Buy
8,171
+23
+0.3% +$1.04K 0.34% 84
2023
Q3 		$350K Buy
8,148
+3,717
+84% +$172K 0.32% 102
2023
Q2 		$243K Sell
4,431
-1,301
-23% -$71.4K 0.22% 157
2023
Q1 		$241K Hold
5,732
– – 0.22% 152
2022
Q4 		$159K Hold
5,732
– – 0.14% 192
2022
Q3 		$147K Sell
5,732
-3,589
-39% -$119K 0.15% 183
2022
Q2 		$336K Buy
9,321
+7
+0.1% +$316 0.34% 105
2022
Q1 		$578K Hold
9,314
– – 0.95% 44
2021
Q4 		$657K Buy
+9,314
New +$662K 0.58% 51

Other funds holding HBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
HP
Harvey Partners Tarrytown, New York $1.26B AUM 64.44% 1-Year Est. Return
AE
AMH Equity Great Neck, New York $80.3M AUM 78.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
2C
272 Capital Dallas, Texas $40M AUM 150.07% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Riverwater Partners's HBIO Position: Q4 2024 in Review

Riverwater Partners sold out of Harvard Bioscience (HBIO) in Q4 2024, closing a stake of 10,341 shares — an estimated $265K sold.

Riverwater Partners first reported a position in HBIO in Q4 2021 and held it in 12 quarters. The position peaked at $657K in Q4 2021. 95 funds tracked by Wall St. Rank hold HBIO as of Q4 2024.

  • Riverwater Partners reported no remaining Harvard Bioscience position as of Q4 2024 after selling out during the quarter.
  • Riverwater Partners sold 10,341 Harvard Bioscience shares in Q4 2024, an estimated $265K.
  • Riverwater Partners first reported a position in Harvard Bioscience in Q4 2021 and held it in 12 quarters.
  • Riverwater Partners's Harvard Bioscience position peaked at $657K in Q4 2021.
  • 95 funds tracked by Wall St. Rank held Harvard Bioscience as of Q4 2024.

Based on Riverwater Partners's 13F filing for Q4 2024, filed 13 Feb 2025.